Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
599 clinical trials found
Clinical trials

ARO-DM1-1001

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who Are =18 to = 65 Years (NCT06138743)

Currently recruiting

ARO-DUX4

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients with Facioscapulohumeral Muscular Dystrophy Type 1 (NCT06131983)

Currently recruiting

AROATXN2

A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2 (NCT06672445)

Currently recruiting

ARTEMIS

ARTEMIS- Effects of Ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction (105277)

Currently recruiting

ARTISTRY

An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens (NCT05502341)

Currently recruiting

ARTISTRY-2

Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® [Bictegravir/Emtricitabine/Tenofovir Alafenamide] in Virologically Suppressed People With HIV-1 [ARTISTRY 2] (NCT06333808)

Currently recruiting

ASCEND

ASCEND - A Randomised, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma (NCT05042128)

No longer recruiting

ASKG315-101

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (NCT05509985)

Currently recruiting

ASPIRE-AF

Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial (NCT03968393)

Currently recruiting

ASSURE

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) (NCT03301506)

Currently recruiting

AT02-001

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects with Systemic Amlyoidosis to Assess the Safety Tolerability, and Pharmacokinetics of AT-02 (NCT05521022)

Currently recruiting

AT02-003

A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02 (NCT05951049)

Currently recruiting

ATIS

Antigen Triggers in Inflammatory Skin-disease (Trial Not Registered)

The study aims to enrol 150 people with inflammatory skin conditions such as psoriasis. The study will collect samples from volunteers. These will be used to try and understand the role of antigen presentation in people with these diseases. Specifically, the research aims to identify pathogenic peptides in lesional vs. Non lesional skin. This could lead to more personalised and effective treatments for psoriasis and ultimately improve patient care.
Currently recruiting

ATLAS 001

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis (NCT06052059)

Currently recruiting

ATLAS 008

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease (NCT06430801)

Currently recruiting

ATRIUM

A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies (NCT05338346)

No longer recruiting

Ava FIRST

Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) – Ava FIRST- a Bayesian Optimal Phase II study (ACTRN12619001042134)

Currently recruiting

Ava NEXT

Avatrombopag in Relapsed or Refractory severe Aplastic Anaemia as EXtra Therapy - Ava NEXT– a Bayesian Optimal Phase II study (ACTRN12619001043123)

Currently recruiting

AWT020

A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer (NCT06092580)

Currently recruiting

AZD0305

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Refractory Multiple Myeloma (NCT06106945)

Currently recruiting
2 3 4 5 6